Trials / Withdrawn
WithdrawnNCT06413511
A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease
A Phase 1b, Dose Escalation, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Participants With Autoimmune Disease
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but active autoimmune disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Belantamab | Belantamab will be administered |
Timeline
- Start date
- 2024-06-03
- Primary completion
- 2025-07-08
- Completion
- 2025-07-08
- First posted
- 2024-05-14
- Last updated
- 2025-08-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06413511. Inclusion in this directory is not an endorsement.